Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering
HOUSTON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing...
Melanoma
Vector Solutions Marks Firefighter Cancer Awareness Month with Expanded Training and Education
Sixth year of training and education support reinforces long-term commitment to firefighter healthTAMPA, Fla., Jan. 13, 2026 /PRNewswire/ -- In...
Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth
Fourth quarter results represent highest quarterly revenue in Company’s historyQ4 year-over-year growth of 35% to 39% driven by sales execution...
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings CallImproves 2025 expected GAAP...
CytomX Therapeutics Announces Business Update and Company Milestones for 2026
- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”)...
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription...
Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis
Integrated software, AI-driven analytics, and frictionless workflows enable customers to harness the full power of biological insightsSAN DIEGO, Jan. 6,...
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
RAMAT GAN, Israel, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company...
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December...
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December...
Oncotelic Therapeutics Details PDAOAI Platform and Opens Access to Its Total TGF-β Knowledge Corpus
PDAOAI PDAOAI Platform and Opens Access to Its Total TGF-β Knowledge Corpus AGOURA HILLS, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE)...
Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio
• Ameluz® and RhodoLED® New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera...
Werewolf Therapeutics Announces Pipeline and Business Updates
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of...
Werewolf Therapeutics Announces Pipeline and Business Updates
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of...
CNS Pharmaceuticals Announces CEO Transition
Industry veteran Rami Levin, MBA appointed as President & Chief Executive Officer HOUSTON, TX / ACCESS Newswire / December 17,...
Landmark Study Shows Combination of Castle Biosciences’ DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests...
Medical Care Technologies, Inc. (OTC Pink:MDCE) Completes First AI Consumer App Targeting Deployment Across 100+ Countries and 30 Languages
Company to Launch AI Food & Recipe App to Access Trillion-Dollar Global Food Market While Advancing Medical AI Pipeline MESA,...
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Scientists developed an antibody treatment that...
Plus Therapeutics Expands CNSide Assay Platform to State of California
CNSide Diagnostics now licensed in 48 U.S. States covering over 90% of the U.S. populationHOUSTON, Dec. 11, 2025 (GLOBE NEWSWIRE)...
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose...